Kornimate/medical-research-clean huggingface dataset:
effects of high-intensity exercise with hypoxia and taurine supplementation on metabolic and mitochondrial parameters

Conditions: Obesity

Summary: the prevalence of obesity in brazil is one of the highest in latin america. as an inflammatory disease, obesity needs to be treated, and one of the best interventions is exercise. this research aims to learn more about the effects of combining high-intensity training, recovery hypoxia, and taurine supplementation. to better understand these effects, the researchers will compare hypoxia and normoxia, as well as taurine and placebo, with all participants training in the same way. the researchers will also investigate mitochondrial respiration and food consumption to connect certain aspects of obesity with overall health.

obesity is characterized by a chronic inflammatory state, often linked with elevated oxidative stress and mitochondrial dysfunction. while physical exercise can trigger inflammatory responses due to muscle damage, it also promotes significant bodily adaptations, particularly in body composition, physical fitness, and skeletal muscle tissue, including enhanced mitochondrial dynamics. moderate hypoxia, when combined with exercise, further amplifies these benefits by increasing the expression of genes related to mitochondrial biogenesis, glut1 expression, and angiogenesis. previous findings suggest that high-intensity physical activity not only improves cardiorespiratory capacity and alters body composition but also significantly elevates inflammation. consequently, taurine, a supplement known for its anti-inflammatory properties and ability to reduce oxidative stress, should be considered to mitigate these issues and optimize the benefits of exercise and hypoxia. based on these premises, it is hypothesized that the combination of taurine supplementation with physical training under recovery hypoxia may reduce the significant rise in pro-inflammatory cytokines, thereby enhancing the potential benefits of exercise and moderate hypoxia.

Eligibility criteria:
inclusion criteria: * women * age between 25 - 45 years old; * bmi between 30 - 35kg/m²; * not be on a diet; * not be on a physical activity program; * not be menopaused. exclusion criteria: * smokers; * alcoholics; * use thyroid medication; * carry out nutritional monitoring or in treatment for weight loss; * hypertension; * metabolical syndrome; * have any comorbidity associated to obesity; * drugs use.

Keywords: mitochondrial disfunction oxidative stress inter-effort hypoxia physical exercise obesity
improving competency and metrics for polypectomy skills using evaluation tools and video feedback (complete)

Conditions: Colorectal Cancer

Summary: i plan to investigate the value of video-based feedback in endoscopic training - specifically, the role of terminal video feedback as compared to usual concurrent feedback on cold snare polypectomy technique in trainees, using direct observation of polypectomy skills (dopys) competency score. i have focused the study on the competency of cold snare polypectomy for subcentimeter polyps. the majority (\>75%) of colon polyps are smaller than one centimeter. cold snare polypectomy has been shown, and recommended by the american society for gastrointestinal endoscopy (asge), to be an effective removal technique. however, its widespread use and moreover, its teaching to trainees is lacking. it takes time and resources to learn and teach endoscopic techniques. our study will hope to identify a mechanism through video-based feedback that could help to improve the translation of the training of polypectomy skills to its actual performance, and to accelerate the learning curve.


Eligibility criteria:
inclusion criteria: * participants: senior level ucsf gastroenterology trainees (2nd and 3rd year gi fellows) rotating at the san francisco veterans affairs medical center (sfvamc). * patients undergoing elective routine colonoscopy procedure. exclusion criteria: * participants: junior level university of california, san francisco (ucsf) gastroenterology trainees (1st year gi fellows) rotating at the san francisco veterans affairs medical center, and senior level trainees who are not rotating at the sfvamc. * patients: patients undergoing undergoing emergency colonoscopy procedure.
chompions! a treatment study for childhood avoidant/restrictive food intake disorder (arfid)

Conditions: ARFID; Picky Eating; Eating Disorders in Children

Summary: avoidant restrictive food intake disorder (arfid) is a disorder that affects toddlers, children, adolescents, and adults. individuals with arfid are not able to consume an adequate amount or variety of food to a degree that it affects their mental and/or physical health. arfid often begins in early childhood so it is important to treat children in early in life as possible to prevent any negative consequences of poor nutrition. there are currently no treatments for young children with arfid. the investigators have developed two different study programs and the purpose of this study is to test them out and see if they help children with arfid and to learn more about how these study programs work.


Eligibility criteria:
inclusion criteria: * child is between 60 and 119 months (5 years and up to 9 years, 11 months) * english speaking * consent given by parent and assent by child and any one or more of the following: * score of 29 or above on the child food neophobia scale * underweight * current diagnosis of arfid * dependent on nutritional supplements to achieve sufficient calories for optimal growth * avoiding activities due to eating rated at least almost always exclusion criteria: * child is known to have a severe intellectual disability based on medical chart review * meets diagnostic criteria for anorexia nervosa or bulimia nervosa * is currently enrolled in a treatment study or receiving active treatment for arfid * taking medications known to affect appetite

Keywords: fbi-arfid eating disorder avoidant restrictive food intake disorder food neophobia treatment for children sensory sensitivity picky eating low weight nutritional deficiencies
safety of an inactivated sars-cov-2 vaccine for prevention of covid-19 in children and adolescents

Conditions: COVID-19

Summary: this study is a multi-center and open design, phase ⅳ clinical trial of an inactivated sars-cov-2 vaccine (coronavac) manufactured by sinovac research and development co., ltd.the purpose of this study is to evaluate the safety of the sars-cov-2 inactivated vaccine in population aged 3\~17 years and in people with pre-existing disease to provide reference for improving the immunization strategy of covid-19 vaccine.

this study is a multi-center and open design, phase ⅳ clinical trial in population aged 3\~17 years . the experimental vaccine will be manufactured by sinovac research and development co.,ltd.the study is planned to be carried out in 11 provinces from august 2021 to december 2022, including liaoning, heilongjiang, anhui, fujian, jiangxi, hubei, guangxi, chongqing, guizhou, yunnan and gansu. each province will serve as a research center, and each research center will select the corresponding research site.a total of 33000 subjects including patients with pre-existing will be enrolled with 3000 for each research center, including 600 subjects aged 3\~5years，1200 subjects aged 6\~11 years,1200 subjects aged 12\~17 years. and subjects will receive two doses of vaccine on day 0 and day 28.

Eligibility criteria:
inclusion criteria: * have not received any covid-19 vaccine in the past or at least one dose of coronavac manufactured by sinovac research and development co.,ltd; * population aged 3\~17 years ; * the subjects can understand and voluntarily sign the informed consent form and participate in the follow-up; exclusion criteria: * history of severe allergy to the vaccine such as acute allergic reaction,angioedema and dyspnea ; * severe neurological disease such as myelitis transverse,guillain-barre syndrome and demyelinating disorders; * acute disease,acute onset of chronic disease and severe chronic diseases.
detecting traumatic intracranial hemorrhage with microwave technology

Conditions: Traumatic Intracranial Hemorrhage

Summary: an open study evaluating the diagnostic accuracy of a microwave-based device to detect traumatic intracranial hemorrhage (tich), by comparing measurements on trauma patients with confirmed vs excluded tich

this open study will enrol trauma patients admitted to the trauma unit, department of surgery at sahlgrenska university hospital/sahlgrenska. it will compare patients where tich has been confirmed by ct (group a) to patients where ct has ruled out tich (group b). patients will be asked to participate in the study as early as possible after admission and ct scan. after physical examination, checking inclusion/exclusion criteria, and after informed consent has been acquired, the baseline microwave-based measurement will be performed. the diagnostic procedure is estimated to take 15 min; whereof total subject measurement time will be less than five minutes. follow-up microwave measurements will be performed in conjunction with any follow-up cts performed as part of the standard of care, during the hospitalized treatment period. if no follow-up cts are performed as part of the standard of care, only the baseline microwave measurement will be performed. safety will be followed throughout the study, and a safety follow-up will be performed 12 hours after the last microwave-based investigation is finalized.

Eligibility criteria:
inclusion criteria: * patient admitted to sahlgrenska university hospital for trauma care. * patient deemed clinically stable. * patient should have a glasgow coma scale rating of \> 14 * tich confirmed (group a) or ruled out (group b) by ct, performed within the latest 12 hours. * patient ≥ 18 years of age. * patient has signed the informed consent form. exclusion criteria: * patient has confirmed or suspected skull fracture. * patient has confirmed or suspected cervical spine fracture. * the diagnostic procedure is deemed to interfere with the standard of care. * patient has a shunt or other foreign object implanted intracranially. * patient has agraffes/other metal parts, thick (\> 1 cm) bandage, or other foreign materials attached to the head that are deemed to interfere with the diagnostic procedure. * any other condition or symptoms preventing the patient from entering the study, according to the investigator's judgment. * females who are pregnant.
observational study on the effect of novomix® 30, levemir® or novorapid® (alone or combined) in type 2 diabetics previously treated with anti-diabetic medication

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in africa, asia, south america and europe. the aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. after the physician's decision to start insulin treatment using novomix® 30, levemir® or novorapid® (alone or combined), type 2 diabetics will be eligible to be included in this study at the physician's discretion


Eligibility criteria:
inclusion criteria: * after the physician has taken the decision to use novomix®30, levemir® or novorapid® (alone or combined), any subject with type 2 diabetes who is not treated with these insulins or who has started on these insulin within the last 4 weeks before inclusion into this study is eligible for the study. * the selection of the subjects will be at the discretion of the individual physician. exclusion criteria: * subjects treated with novomix® 30, levemir® or novorapid® (alone or in combination) for more than 4 weeks before inclusion into this study. * subjects who were previously enrolled in this study. * subjects with a hypersensitivity to novomix® 30, levemir® or novorapid® or to any of the excipients. * women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months.
anti-vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: evaluation for the treatment of diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the primary objective of the study was to compare the efficacy of intravitreal (ivt)-administered regn910-3 compared to intravitreal aflibercept injection (iai) in improving best corrected visual acuity (bcva) in participants with diabetic macular edema (dme).


Eligibility criteria:
key inclusion criteria: 1. men or women ≥18 years of age with type 1 or type 2 diabetes mellitus who have clinically significant dme with central involvement in the study eye 2. bcva etdrs letter score of 73 to 24 (snellen equivalent of 20/40 to 20/320) in the study eye 3. willing and able to comply with clinic visits and study-related procedures 4. provide signed informed consent key exclusion criteria: 1. evidence of macular edema due to any cause other than diabetes mellitus in either eye 2. ivt anti-vegf in the study eye within 12 weeks of the screening visit 3. panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening note: other inclusion/ exclusion criteria apply
integrating targeted medlineplus health prescriptions into clinic practice workflow

Conditions: Allergic Rhinitis; Asthma; Back Pain; Benign Prostatic Hypertrophy; Bursitis; Depression; Anxiety; Diabetes Mellitus; Esophageal Reflux; HIV Infections; Hyperlipidemia; Hypertension; Insomnia; Irritable Bowel Syndrome; Obesity; Osteoporosis (Senile); Shoulder Pain; Sinusitis; Symptomatic Menopause; Urinary Incontinence; Urinary Tract Infection; Vaginitis

Summary: the specific aim of this proposed project is to implement a standard process for integrating medlineplus health information prescriptions into the clinic workflow. hypothesis 1: individuals in the intervention group who receive tailored email health information with provider selected medlineplus links and added commentary for patient specific conditions will be more likely to seek information / use medlineplus compared with individuals in the control group. hypothesis 2: individuals in the intervention group who receive tailored email health information with provider selected medlineplus links and added commentary for patient specific conditions will be more satisfied with the information received compared with individuals in the control group.

providing patient education in an outpatient practice can be challenging in part due to the variety of patient medical conditions and the quantity of materials needed. increasingly, electronic resources such as those found on the internet have the potential to provide easily accessible needed information. however, clinicians do not have the time to assemble a list of websites for their patients and even if they did, the quality of information varies greatly and would require close screening. medlineplus is a free national library of medicine sponsored website that features health information on hundreds of conditions with all information carefully screened for quality standards by expert librarians. we will conduct a pilot study to seamlessly integrate provider-customized medlineplus health education prescriptions for specific conditions into the normal clinic workflow to motivate patients to access and expand their use of medlineplus to benefit their health. as hiv prevention/education is very important, we will include the hiv clinic as well as a general internal medicine clinic.

Eligibility criteria:
inclusion criteria: * to be included in the study population, patients must also be seen by their physician for one of the 21 target health conditions (allergic rhinitis, asthma, back pain, benign prostatic hypertrophy, bursitis, depression/anxiety, diabetes mellitus, esophageal reflux, hiv, hyperlipidemia, hypertension, insomnia, irritable bowel syndrome, obesity, osteoporosis (senile), shoulder pain, sinusitis, symptomatic menopause, urinary incontinence, urinary tract infection, vaginitis) and be willing to provide an email address. * patients will be included only once. * all patients in the intervention and the control group will receive the survey. * all physicians and staff at the fairview clinic and hiv clinic will be invited to complete the physician or staff survey. exclusion criteria: * no email address
a feasibility study of the cordis neurovascular self expanding stent system in intracranial arteries

Conditions: Atherosclerosis; Aneurysm

Summary: feasibility study to assess safety of treating patients with self expanding stent in intracranial arteries.

feasibility study to assess safety of treating patients with self expanding stent in intracranial arteries. patients will be followed for 6 months with assessments related to technical feasibility and adverse events.

Eligibility criteria:
contact site for specific information inclusion criteria: * subject meet specific criteria for treatment * subject must be willing to return to site for 30 day and 6 month follow up evaluations exclusion criteria: * stenting, angioplasty or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to expected enrollment date * previously implanted carotid stent associated with the symptomatic distribution within the past 12 weeks

Keywords: atherosclerosis,wide neck aneurysm
the crnic institute human trisome project biobank

Conditions: Down Syndrome; Trisomy 21

Summary: the human trisome project will significantly increase the speed of down syndrome research and the understanding of associated medical conditions. its biobank will provide de-identified samples to research.

the purpose of this study is to provide qualified and approved researchers with access to biological samples and health information to answer specific research questions. this project will significantly increase the speed of down syndrome research and the understanding of associated medical conditions such as alzheimer's disease, congenital heart defects, autoimmune disorders, autism, and some forms of leukemia. participation includes a blood draw, a mouth swab, and allowing researchers to look at your health information yearly for the next 5 years. optional procedures include providing a urine and/or stool sample and taking part in the study for a longer time frame.

Eligibility criteria:
inclusion criteria: anyone 6 months to 89 years old who: 1. has down syndrome (any type) 2. does not have down syndrome exclusion criteria: 1. prisoners 2. wards of the state
inappropriate polypharmacy in elderly patients in primary care and deprescribing in older patients with frailty

Conditions: Medication Overuse; Deprescriptions; Polypharmacy; Frailty Syndrome

Summary: polypharmacy is a major and growing public health problem occuring within all health care settings worldwide. the systematic review of mansoon et al,2017 identified 138 different definitions for polypharmacy from which the most commonly used numerical definition is being this of five or more medicines. however, numerical definitions do not take into account factors such as comorbidity thus there is a need for a a shift towards the terms "appropriate" ,and "inappropriate polypharmacy" and potentially inappropriate prescribing (pip). the prevalence of polypharmacy varies between 10% to as high as around 90% depending on the definition used and the population that is studied.there is worldwide literature regarding the epidemiology of polypharmacy in the elderly , health outcomes and cost. the is an abundance of guidelines and tools regarding deprescribing, the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy , minimizing inappropriate medication and improving outcomes. in greece , as pointed out by the simpathy project, there is no formal polypharmacy initiative and relative greek literature is scarce.there is no research in greece regarding the prevalence of pip among community-dwelling elderly patients as well as there are no studies evaluating the feasibility or effectiveness of deprescribing interventions in the elderly or older patients with frailty. the aim of this thesis is to record, in the primary care setting in crete, the underlying barriers and enablers of deprescribing among health care professionals and also to evaluate ,the clinical outcomes of deprescribing interventions in primary care. additionally, the beliefs and attitudes of the patients and/or their caregivers towards deprescribing will be recorded.


Eligibility criteria:
inclusion criteria: * community-dwelling patients * age ≥ 65 years * receive at least 5 medication ( polypharmacy ) exclusion criteria: * hospitalized or patients living in nursing home * incapable of giving written consent
neoadjuvant stereotactic body radiotherapy prior to radical prostatectomy for high risk prostate cancer

Conditions: Prostate Cancer

Summary: this is a single-arm prospective non-randomized, non-blinded trial to assess the safety of neoadjuvant stereotactic body radiation therapy (sbrt) before surgery in high risk prostate cancer patients. radiation therapy will be delivered over 5 treatment sessions for approximately 1.5 weeks total.


Eligibility criteria:
inclusion criteria: * subjects must have biopsy-confirmed adenocarcinoma of the prostate. * subjects must have a negative bone scan. * subjects must have one of the following risk factors: * psa ≥20 and/or * gleason score ≥8 and/or * clinical or radiographic stage ≥t3a per ajcc (american joint committee on cancer) 7th edition staging manual and/or * radiographic pelvic lymph node positive disease and/or * at least two out of four of the following: psa (prostate specific antigen) 10-19.9, gs (gleason score) = 3+4, clinical stage = t2b/t2c, ≥50% positive biopsy cores. * subjects must freely sign informed consent to enroll in the study. * subjects must be medically fit to undergo surgery determined by the pi. * age ≥ 18 * kps karnofsky performance status (performance status is an attempt to quantify cancer patients' general well-being and activities of daily life, scores range from 0 to 100 where 100 represents perfect health and 0 represents death): ≥70. * no prior invasive malignancy in the past 3-years, except non-melanomatous skin cancer unless disease free for a minimum of 2 years. carcinoma in-situ of the bladder or head and neck region is permissible. * subjects must not have had prior pelvic radiation therapy, * subjects must not have had prior androgen deprivation therapy in the past 6 months. exclusion criteria: * metastatic disease as demonstrated by bone scan, ct scan or mri (magnetic resonance imaging) of the pelvis, or chest x-ray. * declared high-risk for anesthesia by attending anesthesiologist, cardiologist, or other physician. * history of prior pelvic radiation therapy. * history of androgen deprivation therapy within the past 6 months.